exclude WG, and positive results can be seen in other vasculitides, including microscopic polyangiitis and allergic granulomatous angiitis. Various treatment regimens can result in a complete remission, although relapses do occur. Renal or pulmonary insufficiency and/or complications from therapy can result in morbidity and death.
WG presents clinically as ulcerative and crusted lesions with tissue destruction. The histologic triad of vasculitis, granulomatous inflammation, and biocollagenolytic necrosis is characteristic, but all three findings are uncommon in a single biopsy. The vasculitis involves destruction of small to medium-sized arteries that contain an inflammatory infiltrate within the vessel wall and subendothelial space, leading to destruction of the elastic lamina (figure 1).
From the Department of Pathology, Southern California Permanente Medical Group, Woodland Hills Medical Center, Woodland Hills, Calif.
Figure 1. A: A vessel wall is destroyed by an inflammatory infiltrate. A zone of fibrinoid necrosis is seen. B: A couple of multinucleated giant cells are seen; they are usually isolated. C and D: ANCA can be either cytoplasmic (C) or perinuclear (D). WG is most often associated with c-ANCA.
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INDICATION: ZETONNA® (ciclesonide) Nasal Aerosol is a corticosteroid indicated for the treatment of symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.
IMPORTANT SAFETY INFORMATION:
In clinical studies local nasal eff ects of epistaxis, ulcerations, and nasal septal perforations were observed with ZETONNA® (ciclesonide) Nasal Aerosol. In the short-term and long-term trials combined, nasal septal perforations were reported in 2 patients of 2335 treated with ZETONNA compared with none of 892 treated with placebo. Both perforations occurred in 2-week SAR trials while none occurred in the longer term trials. In clinical trials with another formulation of ciclesonide, the development of localized infections of the nose or pharynx with Candida albicans has occurred. Corticosteroids can interfere with wound healing. Prior to initiating therapy, examine patients for evidence of septal perforation, erosions, ulceration, nasal surgery, and trauma. Avoid spraying ZETONNA directly onto the nasal septum. Avoid use in patients with recent septal perforation, nasal erosion, nasal ulcers, nasal surgery, or nasal trauma. Monitor patients periodically for signs of adverse reactions on the nasal mucosa. Discontinue ZETONNA if erosions, ulcerations or perforations occur. Nasal and inhaled corticosteroids may result in the development of glaucoma and cataracts. Monitor patients closely with a change in vision or with a history of increased intraocular pressure, glaucoma, or cataracts. ZETONNA is contraindicated in patients with a known hypersensitivity to ciclesonide or any of the ingredients of ZETONNA. Cases of hypersensitivity reactions following administration of ciclesonide with manifestations such as angioedema, with swelling of the lips, tongue and pharynx have been reported. Patients using immunosuppressive drugs, like corticosteroids, can cause potential worsening of existing tuberculosis; fungal, bacterial, viral or parasitic infections; or ocular herpes simplex. Chicken pox and measles can have a more serious or even fatal course in susceptible individuals. Use caution in patients with the above because of the potential for worsening of these infections. When intranasal corticosteroids are used at very high dosages or at the regular dosage in susceptible individuals, systemic corticosteroid eff ects such as hypercorticism and adrenal suppression may appear. If such changes occur, discontinue ZETONNA slowly. Corticosteroids may cause a reduction in growth velocity in children. Monitor growth routinely in pediatric patients receiving ZETONNA.
In trials 2-6 weeks in duration, the most common adverse events that occurred with an incidence of at least 2% and more frequently with ZETONNA than with placebo were nasal discomfort, headache and epistaxis. Please see Brief Summary of Prescribing Information on the following pages. [see Adverse Reactions (6)] Nasal Septal Perforation: Nasal septal perforation has been reported in patients following the intranasal application of ZETONNA Nasal Aerosol. Three short-term placebo-controlled trials (2 weeks) and one long-term (26 weeks with placebo control and 26 weeks open-label extension without placebo control) trial were conducted in patients with seasonal and perennial allergic rhinitis. Nasal septal perforations were reported in 2 patients out of 2335 treated with ZETONNA Nasal Aerosol compared with none of 892 treated with placebo.
Before starting ZETONNA Nasal Aerosol conduct a nasal examination to ensure that patients are free of nasal disease other than allergic rhinitis. Periodically monitor patients with nasal examinations during treatment for adverse effects in the nasal cavity. If an adverse reaction (e.g. erosion, ulceration, perforation) is noted, discontinue ZETONNA Nasal Aerosol. Avoid spraying ZETONNA Nasal Aerosol directly onto the nasal septum. Candida Infection: In clinical trials with another formulation of ciclesonide, the development of localized infections of the nose or pharynx with Candida albicans has occurred. If such an infection develops with ZETONNA Nasal Aerosol, it may require treatment with appropriate local therapy and discontinuation of ZETONNA Nasal Aerosol.
Impaired Wound Healing: Because of the inhibitory effect of corticosteroids on wound healing, patients who have experienced recent nasal septal ulcers, nasal surgery, or nasal trauma should not use ZETONNA Nasal Aerosol until healing has occurred.
Glaucoma and Cataracts
Nasal and inhaled corticosteroids may result in the development of glaucoma and cataracts. Therefore, close monitoring is warranted in patients with a change in vision or with a history of increased intraocular pressure, glaucoma, or cataracts.
Hypersensitivity
ZETONNA Nasal Aerosol is contraindicated in patients with a known hypersensitivity to ciclesonide or any of the ingredients of ZETONNA Nasal Aerosol. Cases of hypersensitivity reactions following administration of ciclesonide with manifestations such as angioedema, with swelling of the lips, tongue and pharynx, have been reported.
Immunosuppression
Patients who are using drugs that suppress the immune system are more susceptible to infections than healthy individuals. Chicken pox and measles, for example, can have a more serious or even fatal course in susceptible children or adults using corticosteroids. In children or adults who have not had these diseases or been properly immunized, particular care should be taken to avoid exposure. How the dose, route, and duration of corticosteroid administration affect the risk of developing a disseminated infection is not known. The contribution of the underlying disease or prior corticosteroid treatment to the risk is also not known. If a patient is exposed to chicken pox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If a patient is exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information). If chickenpox develops, treatment with antiviral agents may be considered.
Corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculosis infections of the respiratory tract; or in patients with untreated local or systemic fungal or bacterial infections; systemic viral or parasitic infections; or ocular herpes simplex because of the potential for worsening of these infections.
Hypothalamic-Pituitary-Adrenal Axis Effect
Hypercorticism and Adrenal Suppression: When intranasal corticosteroids are used at higher than recommended dosages or in susceptible individuals at recommended dosages, systemic corticosteroid effects such as hypercorticism and adrenal suppression may appear. If such changes occur, the dosage of ZETONNA Nasal Aerosol should be discontinued slowly, consistent with accepted procedures for discontinuing oral steroid therapy.
The replacement of a systemic corticosteroid with a topical corticosteroid can be accompanied by signs of adrenal insufficiency. In addition, some patients may experience symptoms of corticosteroid withdrawal, e.g., joint and muscular pain, lassitude, and depression. Patients previously treated for prolonged periods with systemic corticosteroids and transferred to topical corticosteroids should be carefully monitored for acute adrenal insufficiency in response to stress. In those patients who have asthma or other clinical conditions requiring long-term systemic corticosteroid treatment, rapid decreases in systemic corticosteroid dosages may cause a severe exacerbation of their symptoms. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Effect on Growth

Adults and Adolescents 12 Years of Age and Older in Short-Term (2-6 weeks) Trials:
In three short-term trials and the first 6 weeks of one long-term trial, conducted in the US, 884 patients with a history of seasonal or perennial allergic rhinitis were treated with ZETONNA Nasal Aerosol 74 mcg daily. Adverse reactions did not differ appreciably based on age, gender, or race. The table below displays reactions that occurred with an incidence of at least 2.0% and more frequently with ZETONNA Nasal Aerosol 74 mcg than with placebo in seasonal or perennial allergic rhinitis clinical trials of 2 to 6 weeks duration. Epistaxis 26 (2.9) 24 (2.7) a Nasal discomfort includes both nasal discomfort and instillation site discomfort When considering the data from higher doses evaluated in the short-term trials, epistaxis demonstrated a dose response. In addition, two patients treated with ZETONNA Nasal Aerosol 74 mcg experienced nasal septal perforations in the short-term trials compared to no patients treated with placebo. Approximately 1.2% of patients treated with ZETONNA Nasal Aerosol 74 mcg in clinical trials discontinued because of adverse reactions; this rate was similar for patients treated with placebo.
Discontinuations due to local adverse reactions were similar in ZETONNA Nasal Aerosol 74 mcg treated patients (0.8%) compared to placebo treated patients (0.8%). Local adverse reactions leading to discontinuation that occurred only in ZETONNA Nasal Aerosol treated patients included ear infection, nasal discomfort, nasal dryness, nasal mucosal/septum disorders, pharyngitis, streptococcal pharyngitis, sinus headache, and tonsillitis. Pediatric Patients Aged 2 to 11 Years: Trials of ZETONNA Nasal Aerosol have not been conducted in pediatric patients aged 2 to 11 years.
Long-Term (26-Week Double-Blind and 26-Week Open-Label) Safety Trial:
In one 26-week double-blind, placebo-controlled safety trial that included 1110 adult and adolescent patients with perennial allergic rhinitis, additional adverse reactions, with an incidence of at least 2%, that occurred more frequently with ZETONNA Nasal Aerosol than with placebo were upper respiratory tract infection, urinary tract infection, oropharyngeal pain, nasal mucosal/septum disorders, viral upper respiratory tract infection, cough, influenza, bronchitis, streptococcal pharyngitis, muscle strain, and nausea. Nasal discomfort (5.7%) and epistaxis (11.4%) were also more frequent in the 26-week safety trial compared to clinical trials 2 to 6 weeks in duration. Nasal mucosal/septum disorders and cough demonstrated a dose response.
Discontinuations due to adverse reactions were higher in ZETONNA Nasal Aerosol treated patients compared to placebo treated patients and demonstrated a dose response. Local adverse reactions leading to discontinuation were also higher in ZETONNA Nasal Aerosol 74 mcg treated patients (1.7%) compared to placebo treated patients (0.7%). The only local adverse reaction leading to discontinuation that occurred in ZETONNA Nasal Aerosol treated patients and was not observed in the 2-to 6-week trials was upper respiratory tract infection.
A total of 824 patients with perennial allergic rhinitis who completed the 26-week double-blind trial enrolled into an open-label extension and received ZETONNA Nasal Aerosol 148 mcg for 26 weeks. Additional adverse reactions, observed with an incidence of at least 2% were sinusitis, nasopharyngitis, and back pain.
A total of 4 nasal septal ulcerations were also reported in the 26-week open-label extension.
There were no reports of nasal septal perforations in the long-term safety trial.
Post-marketing Experience
Additional adverse reactions have been identified during worldwide postmarketing use with other formulations of ciclesonide, ALVESCO ® Inhalation Aerosol and OMNARIS ® Nasal Spray. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
ALVESCO
® Inhalation Aerosol: immediate or delayed hypersensitivity reactions such as angioedema with swelling of the lips, tongue, and pharynx.
OMNARIS
® Nasal Spray: nasal congestion, nasal ulcer, and dizziness. Localized infections of the nose or mouth with Candida albicans have also occurred with OMNARIS ® Nasal Spray.
DRUG INTERACTIONS
In vitro studies and clinical pharmacology studies suggested that desciclesonide has no potential for metabolic drug interactions or protein bindingbased drug interactions [see Clinical Pharmacology (12. 3) in the full prescribing information]. In a drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged. Erythromycin, a moderate inhibitor of cytochrome P450 3A4, had no effect on the pharmacokinetics of either des-ciclesonide or erythromycin following oral inhalation of ciclesonide [see Clinical Pharmacology (12. 3) in the full prescribing information].
USE IN SPECIFIC POPULATIONS 8.1 Pregnancy
Teratogenic Effects: Pregnancy Category C.
There are no adequate and well-controlled trials in pregnant women. ZETONNA Nasal Aerosol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Experience with oral corticosteroids since their introduction in pharmacologic, as opposed to physiologic, doses suggests that rodents are more prone to teratogenic effects from corticosteroids than humans.
Oral administration of ciclesonide in rats at approximately 120 times the maximum recommended human daily intranasal dose (MRHDID) in adults (on a mcg/m 2 basis at a maternal dose of 900 mcg/kg/day) produced no teratogenicity or other fetal effects. However, subcutaneous administration of ciclesonide in rabbits at similar to MRHDID (on a mcg/m 2 basis at a maternal dose of 5 mcg/kg/day) produced fetal toxicity. This included fetal loss, reduced fetal weight, cleft palate, skeletal abnormalities including incomplete ossifications, and skin effects. No toxicity was observed at ¼ of the MRHDID in adults (on a mcg/m 2 basis at a maternal dose of 1 mcg/kg/day).
Nonteratogenic Effects: Hypoadrenalism may occur in infants born of mothers receiving corticosteroids during pregnancy. Such infants should be carefully monitored.
Nursing Mothers
It is not known if ciclesonide is excreted in human milk. However, other corticosteroids are excreted in human milk. In a study with lactating rats, minimal but detectable levels of radiolabeled ciclesonide were recovered in milk. Caution should be used when ZETONNA Nasal Aerosol is administered to nursing women.
Pediatric Use
The safety and effectiveness for seasonal and perennial allergic rhinitis in children 12 years of age and older have been established. The safety and efficacy of ZETONNA Nasal Aerosol for treatment of the symptoms of seasonal and perennial allergic rhinitis in patients 11 years of age and younger have not been established.
Controlled clinical trials have shown that intranasal corticosteroids may cause a reduction in growth velocity in pediatric patients. This effect has been observed in the absence of laboratory evidence of hypothalamicpituitary-adrenal (HPA)-axis suppression, suggesting that growth velocity is a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA-axis function. The longterm effects of this reduction in growth velocity associated with intranasal corticosteroids, including the impact on final adult height, are unknown. The potential for "catch-up" growth following discontinuation of treatment with intranasal corticosteroids has not been adequately studied. The growth of pediatric patients receiving intranasal corticosteroids, including ZETONNA Nasal Aerosol, should be monitored routinely (e.g., via stadiometry). A 52-week, multi-center, double-blind, randomized, placebo-controlled parallelgroup trial was conducted to assess the effect of orally inhaled ciclesonide (ALVESCO ® Inhalation Aerosol) on growth rate in 609 pediatric patients with mild persistent asthma, aged 5 to 8.5 years. Treatment groups included orally inhaled ciclesonide 40 mcg or 160 mcg or placebo given once daily. Growth was measured by stadiometer height during the baseline, treatment and follow-up periods. The primary comparison was the difference in growth rates between ciclesonide 40 and 160 mcg and placebo groups. Conclusions cannot be drawn from this trial because compliance could not be assured. Ciclesonide blood levels were also not measured during the one-year treatment period. There was no difference in efficacy measures between the placebo and the orally inhaled ciclesonide (ALVESCO ® Inhalation Aerosol) groups.
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PATHOLOGY CLINIC
The potential growth effects of prolonged treatment should be weighed against clinical benefits obtained and the availability of safe and effective noncorticosteroid treatment alternatives. To minimize the systemic effects of intranasal corticosteroids, each patient should be titrated to the lowest dose that effectively controls his/her symptoms.
The potential for ZETONNA Nasal Aerosol to cause growth suppression in susceptible patients or when given at higher than recommended dosages cannot be ruled out.
Geriatric Use
Clinical trials of ZETONNA Nasal Aerosol did not include sufficient numbers of patients age 65 and over to determine whether they responded differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
OVERDOSAGE
Chronic overdosage may result in signs or symptoms of hypercorticism [see Warnings and Precautions (5.5)]. There are no data on the effects of acute or chronic overdosage with ZETONNA Nasal Aerosol. A smudgy, dirty, basophilic, ischemic or geographic type of biocollagenolytic necrosis, in which the stromal collagen is destroyed, is quite characteristic (figure 2). Surface ulceration is nonspecific. Granulomatous inflammation is often limited and difficult to find. There are often isolated multinucleated giant cells (figure 1) and occasional epithelioid histiocytes, but well-formed granulomas are not seen. The background inflammation is composed of lymphocytes, histiocytes, neutrophils, eosinophils, and plasma cells.
STORAGE
Histologically, the diagnosis of WG is often one of exclusion. The pathologist must ensure that infections (fungal, mycobacterial, bacterial, viral, and parasitic), cocaine abuse, lymphoma, and Churg-Strauss syndrome, among others, have been ruled out by special studies or clinical evaluation. 
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